531 related articles for article (PubMed ID: 1317657)
1. [Prevention of thrombogenesis in the extracorporeal circuit of hemodialysis with a low molecular heparin: standardization of the dosage with a better hemorrhagic risk/effectiveness ratio].
Barata JD; Oliveira C; Bruges M; Gusmão L; Santana A; Ponce P; Simões J; Freire I; Crespo F; da Silva AN
Acta Med Port; 1992 Feb; 5(2):65-70. PubMed ID: 1317657
[TBL] [Abstract][Full Text] [Related]
2. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
[TBL] [Abstract][Full Text] [Related]
3. Low molecular weight heparin and haemodialysis: neutralization by protaminchloride.
Andrassy K
Blood Coagul Fibrinolysis; 1993 Dec; 4 Suppl 1():S39-43. PubMed ID: 8180328
[TBL] [Abstract][Full Text] [Related]
4. [Appropriate dosage of unfraction heparin and low molecular weight heparin in hemodialysis patients].
Xiao Q; Sun XF; Zhang D; Ma ZF; Wu MG; Wang H; Chen XM
Zhonghua Yi Xue Za Zhi; 2010 Jan; 90(3):187-91. PubMed ID: 20356555
[TBL] [Abstract][Full Text] [Related]
5. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
6. Suppression of intimal hyperplasia with low molecular weight heparin in a sheep model.
Ao PY; Hawthorne WJ; Coombs R; Fletcher JP
Int Angiol; 1999 Jun; 18(2):131-9. PubMed ID: 10424369
[TBL] [Abstract][Full Text] [Related]
7. [Minimal heparinization in dialysis patients with increased risk of bleeding].
Klingel R; Wandel E; Hafner G; Meyer zum Büschenfelde KH; Köhler H
Dtsch Med Wochenschr; 1993 Dec; 118(51-52):1878-83. PubMed ID: 8287777
[TBL] [Abstract][Full Text] [Related]
8. Anticoagulant-free Genius haemodialysis using low molecular weight heparin-coated circuits.
Frank RD; Müller U; Lanzmich R; Groeger C; Floege J
Nephrol Dial Transplant; 2006 Apr; 21(4):1013-8. PubMed ID: 16326745
[TBL] [Abstract][Full Text] [Related]
9. Hemodialysis using heparin-bound Hemophan in patients at risk of bleeding.
Lee KB; Kim B; Lee YH; Yoon SJ; Kang WH; Huh W; Kim DJ; Oh HY; Kim YG
Nephron Clin Pract; 2004; 97(1):c5-10. PubMed ID: 15153761
[TBL] [Abstract][Full Text] [Related]
10. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
Kakkar VV; Howes J; Sharma V; Kadziola Z
Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
[TBL] [Abstract][Full Text] [Related]
11. [The impact of heparin bolus from dysfunctional lumen of dual lumen central venous catheter on activated partial thromboplastin time during hemodialysis: is additional heparinization necessary?].
Sefer S; Kes P; Raić B; Heinrich B; Degoricija V; Szavits-Nossan J
Acta Med Croatica; 2006 Jun; 60(3):281-5. PubMed ID: 16933844
[TBL] [Abstract][Full Text] [Related]
12. [Anticoagulation in hemodialysis sessions with a low molecular weight heparin (CY 222, Choay). Dosage studies in chronic hemodialysis. Its use in patients at high risk of hemorrhage].
Dieval J; Morinière P; Roussel B; Bayrou B; Fournier A; Delobel J
J Mal Vasc; 1987; 12 Suppl B():114-8. PubMed ID: 2834482
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic indications of low molecular weight heparins].
Samama MM; Michaut-Paterno F
Arch Mal Coeur Vaiss; 1991 Nov; 84(11 Suppl):1733-43. PubMed ID: 1662941
[TBL] [Abstract][Full Text] [Related]
14. Comparison of anticoagulation efficacy and clinical safety between imported and domestically manufactured low-molecular-weight heparin during hemodialysis.
Liu ZQ; Wang L
Di Yi Jun Yi Da Xue Xue Bao; 2002 Oct; 22(10):942-3. PubMed ID: 12377628
[TBL] [Abstract][Full Text] [Related]
15. [The use of enoxaparine for anticoagulation in extracorporeal circulation in hemodialysis at high risk for hemorrhage].
Dechelette E; Pouzol P; Jurkovitz C; Kuentz F; Polack B; Cuzin E; Woler M
J Mal Vasc; 1987; 12 Suppl B():105-7. PubMed ID: 2834479
[TBL] [Abstract][Full Text] [Related]
16. Platelet activation in clinical haemodialysis: LMWH as a major contributor to bio-incompatibility?
Gritters M; Borgdorff P; Grooteman MP; Schoorl M; Schoorl M; Bartels PC; Tangelder GJ; Nubé MJ
Nephrol Dial Transplant; 2008 Sep; 23(9):2911-7. PubMed ID: 18364368
[TBL] [Abstract][Full Text] [Related]
17. Activation of coagulation during hemodialysis: effect of blood lines alone and whole extracorporeal circuit.
Lucchi L; Ligabue G; Marietta M; Delnevo A; Malagoli M; Perrone S; Stipo L; Grandi F; Albertazzi A
Artif Organs; 2006 Feb; 30(2):106-10. PubMed ID: 16433843
[TBL] [Abstract][Full Text] [Related]
18. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis.
Bratt G; Törnebohm E; Granqvist S; Aberg W; Lockner D
Thromb Haemost; 1985 Dec; 54(4):813-7. PubMed ID: 3911482
[TBL] [Abstract][Full Text] [Related]
19. Factor Xa-activated whole blood clotting time (Xa-ACT) for bedside monitoring of dalteparin anticoagulation during haemodialysis.
Frank RD; Brandenburg VM; Lanzmich R; Floege J
Nephrol Dial Transplant; 2004 Jun; 19(6):1552-8. PubMed ID: 15034159
[TBL] [Abstract][Full Text] [Related]
20. The safety of heparins in end-stage renal disease.
Sonawane S; Kasbekar N; Berns JS
Semin Dial; 2006; 19(4):305-10. PubMed ID: 16893408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
